GAMIFANT Drug Profile

Summary for Tradename: GAMIFANT

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for GAMIFANT

Recent Clinical Trials for GAMIFANT

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Swedish Orphan Biovitrum	Phase 4
Swedish Orphan Biovitrum	Phase 1
Swedish Orphan Biovitrum	Phase 2

See all GAMIFANT clinical trials

Pharmacology for GAMIFANT

Mechanism of Action	Interferon gamma Antagonists
Established Pharmacologic Class	Interferon gamma Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for GAMIFANT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for GAMIFANT Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for GAMIFANT Derived from Patent Text Search

No patents found based on company disclosures

Gamifant Market Dynamics and Financial Trajectory

Last updated: September 7, 2026

Gamifant, the brand name for emapalumab-lzsg, is Sobi’s high-value biologic for primary hemophagocytic lymphohistiocytosis, or primary HLH. Its commercial profile combines a narrow patient population, severe disease, high treatment intensity, limited direct competition and substantial dependence on specialist diagnosis and transplant-center use. Sobi has reported strong double-digit Gamifant growth since acquiring the product from Novimmune in 2019. The principal long-term risks are market expansion limits, payer scrutiny, clinical competition and eventual biosimilar entry after the U.S. biologic exclusivity period.

What is Gamifant and what FDA indications does it have?

Gamifant is an anti-interferon-gamma monoclonal antibody. It blocks interferon gamma, a cytokine involved in the inflammatory cascade associated with primary HLH.

The FDA approved Gamifant in November 2018 for adult and pediatric patients with primary HLH who have refractory, recurrent or progressive disease, or intolerance to conventional HLH therapy. The product is administered intravenously and is generally used in specialized treatment centers.[1]

Attribute	Gamifant
Active ingredient	Emapalumab-lzsg
Product type	Human monoclonal antibody
Target	Interferon gamma
FDA approval	November 20, 2018
Initial indication	Refractory, recurrent or progressive primary HLH
Administration	Intravenous infusion
Sponsor and commercial owner	Swedish Orphan Biovitrum AB, or Sobi
U.S. regulatory exclusivity	Biologic reference-product exclusivity through approximately November 2030
Primary commercial setting	Specialist hospitals and transplant centers

The approved indication is narrow. Gamifant is not approved broadly for all forms of secondary HLH, macrophage activation syndrome or cytokine storm syndromes, although physicians may investigate or use the mechanism in adjacent conditions through clinical trials or off-label practice.

How large is the Gamifant market?

The addressable market is small in patient count but high in revenue per treated patient. Primary HLH is a rare, life-threatening immune disorder, with treatment concentrated in pediatric hematology, immunology and stem-cell-transplant centers.

The commercial market has three structural characteristics:

1. Treatment is often urgent, reducing the importance of traditional prescription switching.
2. Patient identification depends on specialist diagnosis and genetic or clinical confirmation.
3. Revenue per patient can be substantial because treatment may continue through disease control and hematopoietic stem-cell transplantation.

The principal market expansion opportunity is not a large increase in diagnosed primary HLH patients. It is broader use in earlier treatment, improved diagnosis, expanded international access and clinical development in related hyperinflammatory disorders.

What drives Gamifant demand?

Demand depends on five factors:

• The number of patients diagnosed with primary HLH.
• The speed at which patients are referred to specialist centers.
• Physician acceptance of interferon-gamma blockade.
• Reimbursement for high-cost inpatient biologic therapy.
• The extent to which Gamifant is used as a bridge to stem-cell transplantation.

Gamifant is differentiated from conventional immunochemotherapy because it directly targets interferon gamma. Its use can reduce reliance on broader immunosuppressive regimens in selected patients, although treatment decisions remain highly individualized.

How has Gamifant revenue developed?

Sobi has reported Gamifant as one of its fastest-growing specialty products. Public company reporting indicates that sales expanded materially after Sobi obtained global commercial rights and increased investment in medical education, market access and geographic expansion.

Approximate reported sales progression is shown below. Currency conversions are not included because Sobi reports in Swedish kronor and exchange-rate effects can materially change U.S.-dollar comparisons.

Fiscal year	Gamifant sales, approximately	Commercial trend
2020	SEK 0.8 billion	Early commercial expansion
2021	SEK 1.2 billion	Increased U.S. adoption
2022	SEK 1.5 billion	Continued specialist-center penetration
2023	SEK 1.8 billion	Strong growth across Sobi’s commercial markets
2024	Approximately SEK 2.2-2.4 billion	Continued contribution from U.S. and international markets

Sobi’s reporting should be used as the controlling source for final investment models because figures can differ depending on constant-exchange-rate presentation, regional classification and the treatment of acquired rights.[2-5]

What explains Gamifant’s financial growth?

Gamifant growth has been driven by:

• Increased recognition of primary HLH.
• Greater use in patients who fail or cannot tolerate conventional treatment.
• Expansion of Sobi’s commercial infrastructure.
• Higher treatment intensity and improved access in specialist hospitals.
• International launch activity outside the United States.
• The absence of an approved direct substitute with the same mechanism and indication.

The product also benefits from a relatively concentrated competitive environment. A physician treating a critically ill HLH patient has fewer practical alternatives than a physician prescribing a chronic specialty medicine.

What is Gamifant’s expected financial trajectory?

The most likely trajectory is continued revenue growth followed by moderation as the product matures.

Near-term trajectory

Gamifant should remain a core growth product for Sobi while the company expands diagnosis, reimbursement and use across existing markets. The commercial opportunity remains strongest in the United States, where primary HLH referral networks and specialty reimbursement are more developed.

Revenue growth is likely to remain above the average rate for mature orphan drugs if Sobi achieves:

• Additional country reimbursement.
• Higher use before transplantation.
• Increased diagnosis of genetically confirmed primary HLH.
• Greater physician comfort with first-line or earlier-line use in appropriate cases.
• Positive evidence in adjacent hyperinflammatory conditions.

Medium-term trajectory

Growth is likely to slow as the product reaches a larger share of the diagnosed primary HLH population. The market has a natural ceiling because primary HLH is rare and treatment is concentrated in a limited number of centers.

A reasonable commercial model should separate:

• Patient-volume growth.
• Net price growth.
• Treatment-duration changes.
• Foreign-exchange effects.
• New-indication contribution.
• Future biosimilar erosion.

Price increases alone are unlikely to sustain the historical growth rate indefinitely. The most valuable upside would come from a label expansion supported by prospective clinical evidence.

Long-term trajectory

The principal long-term event is loss of biologic exclusivity. Gamifant’s U.S. reference-product exclusivity period is generally expected to run for 12 years from FDA licensure, placing the key U.S. date around November 2030.[6]

That date does not guarantee immediate biosimilar competition. A biosimilar developer must complete development, obtain FDA approval and resolve or litigate relevant patent issues. Commercial entry could occur after the exclusivity date if a biosimilar is approved and litigation does not block launch.

What is the patent and exclusivity position for Gamifant?

Gamifant is a biologic, so its regulatory protection differs from that of a conventional small-molecule drug.

What is the Orange Book status of Gamifant?

Gamifant does not rely on the traditional Orange Book patent-listing framework used for small-molecule drugs. Biologic reference products are recorded in the FDA Purple Book, while patent and exclusivity analysis proceeds under the Biologics Price Competition and Innovation Act, or BPCIA.[6]

Key protection categories include:

Protection	Relevance to Gamifant
Biologic reference-product exclusivity	Generally 12 years from licensure
Orphan-drug exclusivity	Seven years for the approved orphan indication
Manufacturing and process patents	May restrict biosimilar development or create litigation leverage
Formulation and dosing patents	May protect particular administration schedules or product presentations
Method-of-use patents	May cover defined patient populations or treatment settings
Trade secrets	May protect cell-line, purification and manufacturing know-how

The seven-year orphan exclusivity period began with the 2018 approval and is materially less important than the 12-year biologic exclusivity period for U.S. biosimilar timing. The key economic protection is therefore the reference-product exclusivity period, combined with any valid patents covering the molecule, formulation, dosing regimen or manufacturing process.

Public commercial analysis should distinguish between an FDA exclusivity date and a patent expiration date. They are separate legal rights and can produce different launch outcomes.

What generic or biosimilar entry risks exist?

Traditional generic substitution is not the relevant threat. The relevant risk is biosimilar entry.

A biosimilar competitor would face several barriers:

• Limited patient numbers for clinical development.
• Difficult recruitment in primary HLH.
• High manufacturing complexity.
• Need for analytical comparability to a monoclonal antibody.
• Specialist prescribing and hospital formulary adoption.
• Potential patent litigation under the BPCIA.
• Small commercial market relative to development cost.

These barriers can delay or reduce biosimilar competition. They do not eliminate it. A profitable orphan biologic with a high price per patient can justify development even when the patient population is small.

The likely erosion pattern would be gradual rather than an immediate small-molecule-style collapse. Hospitals may adopt biosimilars selectively, while physicians may continue using the originator in unstable patients or in cases where continuity of therapy is important.

Which companies could challenge Gamifant?

No company has been identified as a leading, publicly established Gamifant biosimilar challenger in the same way that major developers have been identified for high-volume biologics. Potential competitors would most likely include:

• Large biosimilar manufacturers with monoclonal-antibody capabilities.
• Asian and European biologics developers seeking orphan-market entry.
• Contract development and manufacturing organizations partnering with specialty pharmaceutical companies.
• Companies developing alternative therapies for HLH rather than an emapalumab biosimilar.

The competitive threat is broader than direct biosimilar substitution. Emapalumab could face competition from agents targeting other inflammatory pathways, including JAK, IL-1, IL-6 or T-cell activation pathways, depending on clinical evidence and regulatory approvals.

What formulations and manufacturing factors protect Gamifant?

Gamifant is an intravenous biologic supplied for dilution and infusion. Its commercial value depends on more than the antibody sequence.

Potential protection and execution barriers include:

• Cell-line development.
• Upstream culture conditions.
• Purification steps.
• Viral clearance.
• Aggregation control.
• Stability and storage requirements.
• Sterile fill-finish capacity.
• Release testing and comparability data.

These manufacturing barriers can support product durability, but they do not create indefinite exclusivity. A biosimilar sponsor with sufficient analytical and manufacturing expertise can reproduce a highly similar product without copying every proprietary process.

The most defensible commercial advantage may be Sobi’s accumulated clinical experience, specialist relationships, treatment protocols and reimbursement infrastructure rather than a single formulation patent.

What patent litigation and Paragraph IV risks affect Gamifant?

Gamifant is not subject to ordinary small-molecule Paragraph IV litigation in the same form as an ANDA product. Biosimilar developers use the BPCIA patent-exchange and litigation framework instead.[6]

The principal legal risks are:

• A biosimilar sponsor challenging composition-of-matter claims.
• Disputes over formulation or dosing claims.
• Litigation involving manufacturing-process patents.
• Declaratory-judgment actions concerning patent validity or infringement.
• Settlement agreements that establish an agreed biosimilar launch date.

No major publicly reported Gamifant biosimilar settlement or launch agreement has established an earlier market-entry date than the statutory biologic-exclusivity framework. This legal position should be monitored as the 2030 exclusivity window approaches.

How does Gamifant compare with competing HLH therapies?

Therapy category	Example	Main role	Commercial implication
Interferon-gamma blockade	Gamifant	Targeted treatment for refractory, recurrent or progressive primary HLH	High-value orphan biologic with differentiated mechanism
Corticosteroids	Dexamethasone, methylprednisolone	Broad immune suppression	Low-cost background or initial therapy
Chemotherapy-based therapy	Etoposide	Conventional HLH treatment	Established but associated with toxicity
Calcineurin inhibition	Cyclosporine	Immunosuppressive treatment	Used in treatment protocols and combinations
Stem-cell transplantation	Allogeneic transplant	Potentially definitive treatment for primary HLH	Creates bridge-to-transplant demand
Investigational cytokine-pathway agents	Various	Emerging alternatives	Longer-term competitive risk

Gamifant’s main competitive advantage is targeted mechanism and use in severe disease when standard therapy is inadequate or poorly tolerated. Its main disadvantage is price, intravenous administration and dependence on diagnosis by highly specialized clinicians.

What is Gamifant’s revenue exposure for Sobi?

Gamifant is strategically important to Sobi because it is one of the company’s principal growth assets. Revenue concentration creates both operating leverage and product risk.

Positive factors include:

• High unmet need.
• Strong orphan-drug positioning.
• Specialist prescribing.
• Limited direct competition.
• International commercial expansion.
• Potential use as a bridge to transplantation.

Risk factors include:

• Small underlying patient population.
• Dependence on hospital reimbursement.
• Treatment-center concentration.
• Clinical trial risk for label expansion.
• Potential payer controls.
• Future biosimilar competition.
• Reliance on a single mechanism for primary HLH.

A valuation model should avoid treating historical growth as a permanent rate. The base case should assume continued growth through market expansion, followed by maturation before 2030 and greater pricing and volume pressure after biosimilar entry becomes feasible.

What is the commercial outlook for Gamifant?

Gamifant’s commercial outlook remains favorable through the end of the decade. The product has a rare combination of high unmet need, limited approved alternatives, specialist demand and biologic exclusivity.

The strongest upside scenario includes earlier diagnosis, wider reimbursement, international penetration and successful clinical development in adjacent HLH populations. The downside scenario includes stagnant diagnosis rates, payer restrictions, unsuccessful label expansion and biosimilar competition beginning soon after statutory protection expires.

Sobi’s financial trajectory is therefore likely to remain positive in the near term but increasingly dependent on lifecycle management. The company’s ability to preserve value will depend on evidence generation, manufacturing control, international access and protection of the product’s clinical position before the 2030 U.S. exclusivity milestone.

Key Takeaways

• Gamifant is an anti-interferon-gamma biologic approved for refractory, recurrent or progressive primary HLH.
• Sobi has reported rapid sales growth, with annual Gamifant revenue rising from roughly SEK 0.8 billion in 2020 to approximately SEK 2.2-2.4 billion in 2024.
• The market is small by patient count but attractive because treatment intensity and revenue per patient are high.
• U.S. biologic reference-product exclusivity is expected to run to approximately November 2030.
• Biosimilar, rather than traditional generic, competition is the principal post-exclusivity threat.
• The strongest commercial opportunities are diagnosis expansion, international reimbursement and clinical use in adjacent hyperinflammatory conditions.
• The main limitation is the finite primary HLH population and the absence of a large chronic-use market.

FAQs

When does Gamifant lose U.S. exclusivity?

Gamifant’s 12-year U.S. biologic reference-product exclusivity period is generally expected to end around November 22, 2030, based on its November 2018 FDA licensure date.

Is there a generic version of Gamifant?

No conventional generic is expected because Gamifant is a monoclonal antibody. The relevant future competitors are biosimilars.

Is Gamifant listed in the FDA Orange Book?

No. Biologic reference products are generally tracked through the FDA Purple Book rather than the Orange Book.

Can Gamifant be used for secondary HLH?

Gamifant’s FDA indication is for primary HLH in specified refractory, recurrent, progressive or intolerant cases. Use in secondary HLH may occur in clinical research or off-label practice but is not equivalent to an FDA-approved indication.

What is the largest financial risk to Gamifant?

The largest long-term risk is erosion after biologic exclusivity and patent protection weaken. Before then, the principal risks are limited diagnosis, reimbursement constraints and failure to expand use beyond the established primary HLH population.

References

1. U.S. Food and Drug Administration. (2018). FDA approves first treatment for hemophagocytic lymphohistiocytosis.
2. Swedish Orphan Biovitrum AB. (2021). Annual report 2021.
3. Swedish Orphan Biovitrum AB. (2022). Annual report 2022.
4. Swedish Orphan Biovitrum AB. (2023). Annual report 2023.
5. Swedish Orphan Biovitrum AB. (2024). Year-end report and annual reporting for 2024.
6. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products and reference product exclusivity under the Biologics Price Competition and Innovation Act.